Table 1. Characteristics of included RCTs.
| Reference | Country of origin | Jadad scores | Number for interventions | Interventions | Age | Sex (Male/ Female) | N | Follow-up (months) | Nephropathy |
|---|---|---|---|---|---|---|---|---|---|
| Horita et al. (2004) | Japan | 2 | 3 | G1:temocapril 1 mg qd G2:losartan 12.5 mg qd G3: temocapril 1 mg+losartan 12.5 mg qd | G1:39.6 ± 10.8 G2:42.7 ± 12.0 G3:39.6 ± 10.4 | G1:4/6 G2: 5/5 G3:5/6 | 31 | 6 | IgA Nephropathy |
| Maschio et al. (1994) | Italy | 4 | 2 | G1:fosinopril 20 mg qd G2: placebo | NS | NS | 78 | 8 | IgA Nephropathy |
| Nakamura et al. (2007) | Japan | 3 | 3 | G1:olmesartan 10 mg qd G2:temocapril 2 mg qd G3:olmesartan 10 mg+ temocapril 2 mg qd | G1:34 ± 7 G2:31 ± 8 G3:31 ± 7 | G1:5/3 G2:4/4 G3:4/4 |
24 | 3 | IgA Nephropathy |
| Odabas et al. (2001) | Turkey | 2 | 2 | G1:losartan 50 mg qd G2:placebo | G1:34.3 ± 5.9 G2:32.2 ± 4.3 | G1:14/8 G2:14/8 |
44 | 24 | Secondary Amyloidosis |
| Ravid et al. (1993) | Israel | 5 | 2 | G1:enalapril 10 mg qd G2:placebo | G1:43.5 ± 3 G2:44.8 ± 3.5 | G1:21/28 G2:21/24 | 94 | 60 | Diabetic Nephropathy |
| Renke et al. (2004) | Poland | 2 | 3 | G1:losartan 25 mg qd G2: enalapril 10 mg qd G3::losartan 25 mg+enalapril 10 mg qd | G1:40.4 ± 11.9 G2:43.4 ± 10.1 G3:37.7 ± 12.7 | G1:7/11 G2:12/6 G3:11/5 |
52 | 9 | IgA Nephropathy |
| Shen et al. (2012) | China | 3 | 2 | G1:losartan 50 mg qd G2:placebo | G1:50.2 ± 10.4 G2:49.1 ± 11.5 | G1:58/54 G2:56/58 | 226 | 12 | Nondiabetic Chronic Kidney Disease |
| Shimizu et al. (2008) | Japan | 3 | 2 | G1:losartan 12.5 mg qd G2:placebo | G1:36.0 ± 8.5 G2:35.7 ± 8.1 | G1:11/7 G2:6/12 |
36 | 12 | IgA Nephropathy |
| Kosmadakis et al. (2010) | Greece | 2 | 2 | G1:lisinopril 10 mg qd G2:losartan 100 mg qd | G1:52.1 ± 15.3 G2:50.5 ± 15.5 | G1:6/7 G2:7/7 |
27 | 12 | idiopathic membranous nephropathy |
| Acbay (2001) | Turkey | 2 | 2 | G1:enalapril 5 mg qd G2:losartan 25 mg qd | Total:29.4 ± 5.2 | NS | 16 | 2 | Diabetic Nephropathy |
| Usta et al. (2003) | Turkey | 3 | 2 | G1:losartan 50 mg qd G2:placebo | G1:32 ± 10 G2:32 ± 13 | G1:8/5 G2:6/4 |
23 | 12 | Focal Segmental Glomerular Sclerosis |
| Agha et al. (2009) | Pakistan | 3 | 2 | G1:losartan 50 mg qd G2:placebo | G1:53.9 ± 11.1 G2:54.7 ± 10.9 | NS | 361 | 6 | Diabetic Nephropathy |
| Atmaca & Gedik (2006) | Turkey | 2 | 3 | G1: lisinopril 10 mg qd G2:losartan 50 mg qd G3:lisinopril 10 mg+losartan 50 mg qd | G1:55.1 ± 8.9 G2:55.1 ± 9.2 G3:55.1 ± 9.6 | G1:4/5 G2:4/5 G3:3/5 |
26 | 12 | Diabetic Nephropathy |
| Nakamura et al. (2002) | Japan | 3 | 4 | G1:trandolapril 2 mg qd G2:candesartan 8 mg qd G3:trandolapril 2 mg+candesartan 8 mg qd | G1:57.0 ± 9.5 G2:56.5 ± 10.0 G3:57.8 ± 9.0 G4:54.8 ± 9.3 | G:10/5 G2:11/4 G3:10/5 |
60 | 18 | Diabetic Nephropathy |
Notes.
- NS
- not state
- G1
- Group 1
- G2
- Group 2
- G3
- Group 3
- G4
- Group 4
Values are mean [SD].